WO2006054773A1 - Activation de la caspase lors de l'etape de division cellulaire des cellules cancereuses et utilisation de l’inibiteur de la caspase dans un agent anticancereux et autres - Google Patents

Activation de la caspase lors de l'etape de division cellulaire des cellules cancereuses et utilisation de l’inibiteur de la caspase dans un agent anticancereux et autres Download PDF

Info

Publication number
WO2006054773A1
WO2006054773A1 PCT/JP2005/021470 JP2005021470W WO2006054773A1 WO 2006054773 A1 WO2006054773 A1 WO 2006054773A1 JP 2005021470 W JP2005021470 W JP 2005021470W WO 2006054773 A1 WO2006054773 A1 WO 2006054773A1
Authority
WO
WIPO (PCT)
Prior art keywords
caspase
cancer
cells
inhibitor
cancer cells
Prior art date
Application number
PCT/JP2005/021470
Other languages
English (en)
Japanese (ja)
Inventor
Shinji Kamada
Ushio Kikkawa
Toshiaki Hashimoto
Original Assignee
Shinji Kamada
Ushio Kikkawa
Toshiaki Hashimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinji Kamada, Ushio Kikkawa, Toshiaki Hashimoto filed Critical Shinji Kamada
Publication of WO2006054773A1 publication Critical patent/WO2006054773A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • caspase inhibitors Activation of caspases during cancer cell division and use of caspase inhibitors as anticancer agents
  • the present invention relates to the use of a caspase inhibitor as an anticancer agent. More specifically, the present invention has found a cancer cell growth inhibitory effect as a new effect of a caspase inhibitor. It is used as an agent, functional food with anti-cancer effect, or supplement.
  • Apoptosis is a major mechanism for eliminating cells that are no longer necessary for a living body.
  • Apoptosis dysregulation i.e., excessive apoptosis, or failure to apoptose, is associated with many diseases such as acute inflammation, autoimmune diseases, ischemic diseases, and neurodegenerative diseases (see below).
  • Caspase is a cysteine protease having a cysteine residue at the active center and has the activity of cleaving the C-terminal side of aspartate.
  • Caspase is synthesized as an inactive proenzyme (pr oform) and is composed of three regions. Prodomain, large subunit, and small subunit are called prodomain, large subunit, and small subunit from the N-terminal side, and proteolytic processing occurs between the domains, and the large and small subunits form heterodimers and become tetramers. (Active form) (non-patent documents 1 and 3 described later).
  • caspases 14 types have been identified from mammals, and they are roughly classified into those involved in the execution of apoptosis and those involved in the inflammatory response. Further, those involved in apoptosis are classified into an initiator-caspase that functions upstream and an effector-caspase that functions downstream.
  • the initiator-caspase has a long prodomain, and is activated by binding to an adapter molecule in this region, and includes caspases 2, 8, 9, and 10.
  • the effector caspase has a short prodomain, and is cleaved at the C-terminal side of aspartic acid by the cytheter caspase. It is divided into groups and activated. Effector caspases include caspases 3, 6, and 7. An activated effector caspase performs apoptosis by cleaving various substrates (Non-patent Documents 1, 3, 4 described later).
  • caspase inhibitors have been developed and identified.
  • Substances that inhibit caspase enzyme activity include naturally occurring inhibitory proteins and artificially chemically synthesized peptide inhibitors.
  • Naturally occurring inhibitory proteins include IAP family proteins (for example, cIAPl, cIAP2, XIAP, survivin, etc.), p35 protein derived from baculovirus, and crmA protein derived from cowpox virus.
  • the peptide inhibitor rz-Asp-CH2-DCBj described later is described in Patent Document 14 described later.
  • caspase inhibitors suppress liver-myocardium, kidney, intestine, and brain ischemia-induced apoptosis caused by reperfusion, and preserve the function of these organs.
  • Non-patent document 5-9 described later caspase inhibitors suppress neuronal apoptosis due to traumatic brain injury, atrophic lateral sclerosis, Parkinson's disease, etc. in preclinical studies using animal models.
  • caspase is considered to be a major factor in the execution of apoptosis, and research and development have been conducted for the treatment of various diseases caused by abnormal apoptosis by negatively controlling its activity.
  • new functions of caspases have been reported. For example, cell proliferation, cell motility, cell cycle control, cell differentiation, etc., but the detailed mechanism remains unclear (Non-patent Documents 13-17 below).
  • Patent Document 1 US Patent No. 5985838
  • Patent Document 2 US Patent No. 6576614
  • Patent Document 3 Japanese Patent Application Laid-Open No. 7-025865
  • Patent Document 4 Japanese Patent Laid-Open No. 7-069894
  • Non-patent literature l Thornberry et al., Science, 281, 1312-1316 (1998)
  • Non-Patent Document 2 Nicholson et al., Nature, 407, 810-816 (2000)
  • Non-Patent Document 3 Earnshaw et al., Annu. Rev. Biochem., 68, 383-424 (1999)
  • Non-Patent Document 4 Fischer et al., Cell Death Differ., 10, 76-100 (2003)
  • Non-Patent Document 5 Cursio et al "FASEB J., 13, 253-261 (1999)
  • Non-Patent Document 6 Mocanu et al., Br. J. Pharmacol, 130, 197-200 (2000)
  • Non-Patent Document 7 Farber et al., J. Vase. Surg., 30, 752-760 (1999)
  • Non-Patent Document 8 Daemen et al., J. Clin. Invest., 104, 541-549 (1999)
  • Non-patent document 9 Endres et al., J. Cereb. Blood Flow Metab., 18, 238-247 (1998)
  • Non-patent document 10 Yakovlev et al., J. Neurosci., 17, 7415-7424 (1997)
  • Non-patent literature ll Li et al "Science, 288, 335-339 (2000)
  • Non-Patent Document 12 Schierle et al., Nature Med., 5, 97-100 (1999)
  • Non-Patent Document 13 Los et al., Trends Immunol. 22, 31-34 (2001)
  • Non-Patent Document 14 Algeciras- Schimnich et al., Curr. Opin. Cell Biol. 14, 721-726 (200
  • Non-patent document 15 Schwerk et al., Biochem. Pharmacol. 66, 1453-1458 (2003)
  • Non-patent document 16 Newton et al., Genes Dev. 17, 819-825 (2003)
  • Non-Patent Document 17 Woo et al, Nature Immunol. 4, 1016-1022 (2003)
  • Non-Patent Document 18 Yang et al., Cancer Res., 63, 6815-6824 (2003)
  • Non-Patent Document 19 Satoh et al., Cancer, 92, 271-278 (2001)
  • Non-Patent Document 20 Ambrosini et al., Nat. Med. 3, 917-921 (1997)
  • Non-Patent Document 21 Serela et al., Ann. Surg. Oncol, 8, 305-310 (2001)
  • Non-Patent Document 22 Tanaka et al., Clin. Cancer Res., 6, 127-134 (2000)
  • Non-Patent Document 23 Ferreira et al., Ann. Oncol, 12, 799-805 (2001)
  • Non-Patent Document 24 Li et al., Endocrinology, 142, 370-380 (2001)
  • Non-Patent Document 25 Sasaki et al., Cancer Res., 60, 5659-5666 (2000)
  • Non-Patent Document 26 Liston et al., Nat. Cell Biol, 3, 128-133 (2001)
  • Non-Patent Document 27 Mesri et al "J. Clin. Investig., 108, 981-990 (2001)
  • Non-Patent Document 28 Schimmer et al., Cancer Cell, 5, 25-35 (2004)
  • the present invention has been made in view of the above-described circumstances, and the object thereof is the physiological role of caspase in cancer cells, and the availability of caspase inhibitors as anticancer agents.
  • the aim is to provide new anti-cancer drugs targeting caspases based on the findings.
  • the present inventor has (1) that an active form of caspase is detected specifically in the cell division stage of cancer cells, and (2) a caspase inhibitor. Administration of this drug causes delay in cell division in cancer cells, inhibits normal chromosomal segregation during mitosis, and (3) administers a caspase inhibitor.
  • a caspase inhibitor For cancer cells derived from liver cancer, cervical cancer, and acute T-cell leukemia
  • the inventors have found that a growth inhibitory effect has been recognized, and have completed the present invention.
  • the present invention includes the following inventions as medically and industrially useful inventions.
  • a pile cancer agent containing a caspase inhibitor as an active ingredient includes (1) substances that have a substrate-like structure, etc., that bind to the active site of caspase, thereby inhibiting the activity of force spurase, and (2) interact with sites other than the active site. , A substance that inhibits caspase activity, (3) a substance that inhibits caspase activity and inhibits force spase, and (4) a substance that inhibits and inhibits caspase expression. Substances that directly or indirectly inhibit caspases, such as substances, are widely included.
  • An anticancer agent comprising as an active ingredient any one or more of caspases 1, 3, 4, 7, 8, and 9.
  • H A method for suppressing the growth of cancer cells by introducing RNA that specifically suppresses the expression of caspase protein into the cancer cells.
  • RNA may be a siRNA (short interference RNA: also referred to as “short interfering RNA”, “small interfering RNA”, etc.) or an RNAi expression vector (“siRNA expression vector”). ). siRNA and RNAi expression vectors can be designed according to known methods based on the gene sequence of the caspase to be suppressed (for example, Ambion TechNotes 9 (1): 3-5 (2002), Proc. Natl. Acad. Sci. USA 99 (8): 5515-5520 (2002), Proc. Natl. Acad. Sci. USA 99 (9): 6047-6052 (2 002), Nature Biotechnology 20: 505-508 (2002) )).
  • the RNAi expression vector (1) is designed to express dsRNA having a hairpin structure of an appropriate length with a single RNA in the target cell, (2) sense strand, antisense strand Any of those designed to express and associate with each other in the target cell may be used.
  • RNA can be introduced into cancer cells according to a conventional method (see, for example, Nature 411: 494-498 (2001), Science 296: 550-553 (2002)). It is also possible to use the method developed in (1).
  • Stake cancer agent consisting of RNA that specifically suppresses caspase protein expression, or RNAi expression vector constructed to express the RNA in target cancer cells.
  • RNAi expression vector a viral vector, plasmid, phage, cosmid or the like can be used, and a promoter that functions in the target cancer cell (for example, an RNA polymerase III promoter such as U6 or H1 promoter, or RNA polymerase II promoters etc.) may be used that are incorporated upstream of the siRNA sequence that expresses it.
  • a promoter that functions in the target cancer cell for example, an RNA polymerase III promoter such as U6 or H1 promoter, or RNA polymerase II promoters etc.
  • caspase protein expression is sufficient if it substantially reduces the expression level of caspase protein in the target cancer cell. Caspase protein expression is completely suppressed. It does not have to be.
  • the invention's effect utilizes a caspase inhibitor as an anticancer agent or a functional food having an anticancer effect.
  • caspase inhibitors have been researched and developed from the viewpoint of suppressing / preventing apoptosis (for example, treatment of neurodegenerative diseases caused by abnormal apoptosis).
  • the present invention has been found that caspases are activated during the cell division phase of cancer cells and are involved in the control thereof. Further, based on this finding, a new use of suppressing the growth of cancer cells by caspase inhibitors is provided. It is to provide.
  • the growth of cancer cells can be suppressed by inhibiting caspases that are thought to play an important role in the execution of apoptosis.
  • caspase activity is increased, and caspase inhibitors are likely to act specifically on cancer cells.
  • Conventional acupuncture, radiation therapy, etc. used for cancer treatment are aimed at inducing apoptosis in cells, and have a great influence on normal cells other than cancer cells. The effect is a big problem.
  • the anticancer agent of the present invention that targets a caspase that specifically activates cancer cells, the establishment of a new type of cancer treatment method that has extremely low side effects and is unprecedented can be expected.
  • FIG. 1 is a diagram showing the activity of caspase 3 specific to cell division phase by immunofluorescence staining.
  • (a) is the result of using an antibody that recognizes the large subunit of caspase 3 (pi 7)
  • (b) is the result of using an antibody that recognizes the small subunit of caspase 3 (pi 2)
  • FIG. 2 is a diagram showing the results of examining caspase activity during cell division by treating hepatoma-derived HepG2 cells with nocodazole.
  • A shows the results of cell cycle analysis by flow cytometry
  • b shows the results of examining the activity of caspase by Western blotting and the presence or absence of substrate cleavage by caspase.
  • FIG. 3 shows the results of examining caspase activity during cell division by treating cervical cancer-derived HeLa cells with thymidine.
  • A shows the results of cell cycle analysis by flow cytometry.
  • B shows the activity of caspase and caspase by Western blotting. The result of having investigated the presence or absence of the substrate cleavage by a case is shown.
  • FIG. 4 is a graph showing the delay in cell cycle progression by caspase inhibitors.
  • FIG. 5 is a graph showing an increase in the number of cells having condensed nuclei by caspase inhibitors.
  • FIG. 6 is a diagram showing inhibition of progression of chromosome segregation during cell division by caspase inhibitors.
  • FIG. 7 is a graph showing the effect of suppressing proliferation of cancer cells by a general-purpose caspase inhibitor.
  • FIG. 8 is a graph showing the growth inhibitory effect of each caspase-specific inhibitor on HepG2 cells.
  • the anticancer agent of the present invention comprises a caspase inhibitor, that is, a caspase inhibitor as an active ingredient.
  • a caspase inhibitor that is, a caspase inhibitor as an active ingredient.
  • administration of several caspase inhibitors actually suppressed and inhibited the growth of hepatoma-derived HepG2 cells and cervical cancer-derived HeLa cells. ( Figures 7 and 8).
  • caspases are active during apoptosis and positively control apoptosis, so inhibitors have been used to suppress apoptosis.
  • the present inventor newly discovered that caspases are activated specifically in the cell division phase in cancer cells such as HepG2 cells and HeLa cells in the process of elucidating the various physiological roles of caspases. ( Figure 1-3).
  • administration of caspase inhibitors slowed cell cycle progression in cancer cells and inhibited normal chromosome segregation during mitosis (Figure 46). Details will be described later.
  • the present invention confirms the growth inhibitory effect of caspase inhibitors against cancer cells derived from liver cancer and cervical cancer, and provides anticancer drugs against caspase inhibitors. It provides a novel method of use as an agent.
  • the caspase inhibitor also suppressed the proliferation of urkat cells due to acute T cell leukemia (FIG. 7)
  • the anticancer agent of the present invention can also be used for the treatment of cancer such as leukemia.
  • caspase activity in a non-apoptotic state in cancer cells has been reported in prostate cancer, breast cancer, colon cancer, etc., and therefore caspase inhibitors can also be used against these cancer cells. May suppress proliferation.
  • caspase activity in cancer cells in a non-apoptotic state is widely recognized, it becomes possible to use caspase inhibitors as anticancer agents by inhibiting growth for all cancers. .
  • the anticancer agent of the present invention can be applied to cancer cells in which caspase activation is observed in the cell division phase.
  • examples include use in various solid cancers such as cervical cancer and squamous cell carcinomas such as cervical cancer.
  • the type of caspase to be inhibited by the caspase inhibitor is not particularly limited, but the caspase 1, 3, 4, 7, 8, and 9 inhibitors were actually observed to have a growth inhibitory effect. Therefore (FIG. 8), it is preferable to use a caspase inhibitor that inhibits one or more of caspases 1, 3, 4, 7, 8, and 9.
  • activity in the mitotic phase has been confirmed in liver cancer, cervical cancer, etc., where the use of inhibitors of caspases 1, 3, 4, and 7 that have a high growth inhibitory effect is preferred.
  • Particularly preferred is the use of inhibitors against caspases 3,7.
  • a general-purpose caspase inhibitor that inhibits multiple types of caspases may be used, or a caspase inhibitor that controls upstream activity of caspase 3 and the like may be used.
  • the caspase inhibitor may be any of a peptide compound, a non-peptide compound, or a biological protein.
  • peptidic compounds include artificially chemically synthesized peptidic compounds (1) to (8) below.
  • Z-Asp-CH2-DCB in (1) is the official name Benzyloxycarbo-Lu L-Spartau 1-Lu [(2, 6-Dichloro-benzo Noreno 3- r)] methane (Benzyloxycarbonyl— L— Aspart— 1— y ([2,6—Dichlorobenzoyl) oxy ”me thane).
  • Boc-Asp (OMe) -FMK is the official name N— (tert-butoxycarbo-nore) aspanoretinore (O-methinore)- Fnorolelomethinoleketone (N- (tert-butoxycarbonyl) aspartyl (0-methyl) -fluoromethylketone).
  • Boc- Asp (OBzl) -CMK is the official name N ⁇ (tert-butoxycarbo -L) Aspartyl (O-benzyl) Chloromethylketone (N- (tert-Dutoxycarbonyl) aspartyl (0-benzyl)-chioromethylketone) & Z- Asp- CH2- DCB ⁇ Boc- Asp (OMe)-FMK ⁇ Boc- Asp (OBzl) -CMK inhibited the growth of HepG2 cells, HeLa cells, and Jurkat cells in a concentration-dependent manner (Fig. 7). CMK, Z-Asp-CH2-DCB, and Boc-Asp (OMe) -FMK were favorable in this order.
  • the above (4) is a caspase 1 inhibitor, and cell membrane permeability is present on the N-terminal side of the 4 amino acids of YVAD (ie, tyrosine monoparin / alanine / aspartate) involved in caspase 1 inhibition.
  • YVAD tyrosine monoparin / alanine / aspartate
  • a hydrophobic region of force-positive fibroblast growth factor (Kaposi fibroblast growth factor) having the following amino acid sequence ability is added.
  • Amino acid ⁇ ⁇ ⁇ U AAVALLPAVLLALLAP (ie, Alanine, Alanine, Parin, Lanin, Leucine, Leucine, Proline, Alanine, and Parin, Leucine, Leucine, Alanine, Leucine, Leucine, Alanine, Proline)
  • the above (5) is a caspase 3 and 7 inhibitor, and permeates through the cell membrane on the N-terminal side of the 4 amino acids of DEVD (ie, aspartate glutamate monoparin aspartate) involved in the inhibition of caspase 3 and 7. In order to enhance the properties, a hydrophobic region of the force positive fibroblast growth factor is added.
  • the above (6) is a caspase 4 inhibitor. Cell membrane permeability is increased on the N-terminal side of the 4 amino acids of LEVD (ie, leucine monoglutamate monoparin monoaspartate) involved in the inhibition of caspase 4. To enhance, a hydrophobic region of the force positive fibroblast growth factor is given.
  • the above (7) is a caspase 8 inhibitor, and it has cell membrane permeability on the N-terminal side of 4 amino acids of IETD (ie isoleucine glutamate 1 threonine 1 aspartate) involved in caspase 8 inhibition. In order to enhance, a hydrophobic region of the force positive fibroblast growth factor is added.
  • IETD ie isoleucine glutamate 1 threonine 1 aspartate
  • the above (8) is a caspase 9 inhibitor, in order to enhance cell membrane permeability on the N-terminal side of the 4 amino acids of LEHD (ie, leucine glutamate histidine aspartate) involved in caspase 9 inhibition.
  • LEHD leucine glutamate histidine aspartate
  • the hydrophobic region of the force positive fibroblast growth factor is given.
  • the compounds of (4) to (8) above have an acetyl group (Ac) on the N-terminal side and an aldehyde group (CHO) on the C-terminal side of the oligopeptide having a total of 20 amino acids.
  • Ac acetyl group
  • CHO aldehyde group
  • the compounds (1) to (8) can be easily produced by using known chemical synthesis methods such as various existing peptide synthesis methods.
  • peptide compounds are not limited to these compounds, and other peptide compounds that can suppress / inhibit caspase activity may be used in the anticancer agent of the present invention. Oh ,.
  • Non-peptide compound caspase inhibitors include (1) anlinoqu inazolines (AQZs) -AstraZeneca Pharmaceuticals (Scott et al "J. Pnarmacol. Exp. Ther. 304, 433-440 ( 2003)), (2) M826-Merck Frosst (Han et al., J. Biol. Chem. 277, 30128-30136 (2002)), (3) M867-Merck Frosst (Methot et al., J. Exp. Med. 199, 199-207 (2004)), (4) Nicotinyl aspartyl ketones-Merck Frosst (Isabel et al., Bioorg. Med. Chem. Lett. 13, 2137-2140 (2003) )), Etc.
  • Biologically derived proteins include IAP family proteins (eg cIAPl, cIAP2, XIAP, survivin, etc.) that are caspase activity-inhibiting proteins, p35 protein derived from vaccinia virus, crmA protein derived from cowpox virus, etc. Can be illustrated. By expressing these proteins specifically for cancer cells, it is possible to suppress the growth of cancer cells. Examples of a method for expressing a protein in cancer cells include use of a gene expression vector encoding the protein. In the case of this method, the modified protein may be expressed artificially by substituting, deleting, inserting, and Z or adding one or several bases in the base sequence of the gene expression vector according to a conventional method. Good.
  • caspase inhibitors include RNA that specifically suppresses caspase protein expression, and RNAi expression vectors constructed to express the RNA in target cancer cells, as described above.
  • siRNA that suppresses the expression of caspase protein can be used for cancer treatment.
  • vectors and nucleic acids can be used to transfer specific vectors or nucleic acids in order to efficiently and selectively introduce siRNA into target cancer cells.
  • Known carriers and drug delivery systems proposed to be transported to specific cells can be used.
  • siRNA and RNAi expression vectors can be designed based on the caspase gene sequence as described above.
  • the cDNA sequence and amino acid sequence of human caspase 3 are disclosed in DDBJ / EMBL / GenBank databases, such as accession numbers “NM_004346” and “NM_032991,” and the target sequence is determined based on these sequence information. It is possible to design and prepare siRNA and RNAi expression vectors that can be determined and suppress caspase protein expression.
  • the anticancer agent of the present invention is a caspase inhibitor, that is, a caspase inhibitory substance as an active ingredient. Not only a known caspase inhibitor but also a caspase inhibitor found in the future. May be used.
  • Caspase inhibitors include (1) substances that have a substrate-like structure, etc., that bind to the active site of caspase, thereby inhibiting the activity of force spurase, and (2) interact with sites other than the active site. , A substance that inhibits caspase activity, (3) a substance that inhibits caspase activity and inhibits force spase, and (4) a substance that inhibits and inhibits caspase expression.
  • Substances that directly or indirectly inhibit caspases are widely included.
  • a substance that suppresses apoptosis can also be said to be a substance that directly or indirectly inhibits caspase, and as a caspase inhibitor of the present invention. Can be used.
  • the degree of inhibition is not particularly limited, but in a normal enzyme activity assay performed in vivo or in vitro, a 50% inhibitory concentration is used. It is preferable to have a high inhibitory activity of several picomoles (pM) to several tens of micromoles M), in vivo several micromoles M) or less, and in vitro, several hundred nanomoles (nM) or less. More preferred,
  • a caspase inhibitor is used as an anticancer agent (anticancer agent).
  • a caspase inhibitor is a food such as a functional food or a supplement (edible composition). Food with anti-cancer and cancer-preventing effects It can also be used for product development. Alternatively, it can be used as a raw material for cosmetics, and can be used to develop cosmetics that have anticancer effects and cancer prevention effects.
  • the caspase inhibitor can be administered to humans (or animals) as it is or as a pharmaceutical composition together with a conventional pharmaceutical preparation carrier.
  • the dosage form of the pharmaceutical composition is not particularly limited and may be appropriately selected as necessary.
  • oral preparations such as tablets, capsules, granules, fine granules, powders, injections, etc.
  • Parenterals such as suppositories, suppositories, and coating agents.
  • Oral preparations such as tablets, capsules, granules, fine granules, powders and the like are commonly used, for example, starch, lactose, sucrose, trenorose, mannitol, carboxymethylcellulose, corn starch, inorganic salts, etc. Manufactured according to.
  • the amount of caspase inhibitor in these preparations is not particularly limited and can be set as appropriate.
  • binders, disintegrants, surfactants, lubricants, fluidity promoters, corrigents, colorants, flavors, and the like can be appropriately used.
  • parenteral agents the dosage is adjusted according to the patient's age, weight, disease severity, etc., for example, intravenous injection, intravenous infusion, subcutaneous injection, intraperitoneal injection, intramuscular injection, intratumoral injection For example, systemically or locally.
  • This parenteral preparation is produced according to a conventional method, and distilled water for injection, physiological saline and the like can be generally used as a diluent. Further, if necessary, bactericides, preservatives and stabilizers may be added.
  • this parenteral preparation can be frozen after filling in a vial or the like, water can be removed by ordinary freeze-drying treatment, and the liquid preparation can be re-prepared from the freeze-dried product immediately before use.
  • an isotonic agent, stabilizer, preservative, and soothing agent may be added as necessary.
  • the compounding amount of the caspase inhibitor in these preparations is not particularly limited and can be arbitrarily set.
  • parenteral agents include liquid preparations for external use, coating agents such as ointments, suppositories for rectal administration, etc., and these are also produced according to conventional methods.
  • a caspase inhibitor or a gene expression vector encoding a protein acting as an inhibitor is enclosed in a carrier such as a ribosome. It may be administered. At this time, the target site (cancer cell) is specific If a carrier that recognizes the target is used, the caspase inhibitor can be efficiently transported to the target site.
  • the caspase inhibitor can be used in foods (edible compositions) such as supplements and functional foods.
  • foods edible compositions
  • it is added to caspase inhibitors as raw materials for various beverages and various processed foods, and if necessary, it can be added to pellets, tablets, granules, etc. together with excipients such as dextrin, lactose, starch, flavorings, pigments, etc. It can be processed, or coated with gelatin and molded into capsules for use as health food or health food.
  • foods edible compositions
  • excipients such as dextrin, lactose, starch, flavorings, pigments, etc.
  • It can be processed, or coated with gelatin and molded into capsules for use as health food or health food.
  • HepG2 cells derived from hepatoma cells were seeded at 2 x 10 5 cells per well in a 6-well dish with a cover glass in the bottom and cultured for 24 hours. 3. After fixing with phosphate buffer containing 7% formaldehyde for 10 minutes, wash twice with phosphate buffer, treat with phosphate buffer containing 0.5% Triton X-100 for 10 minutes, Washed twice with phosphate buffer.
  • the cells treated in this manner were subjected to 4 ° overnight in a phosphate buffer (containing 1% ushi serum albumin) containing anti-active caspase 3 antibody and anti-tubulin antibody as primary antibodies. Incubation with C. After washing twice with phosphate buffer, it was incubated for 10 minutes in a phosphate buffer containing a secondary antibody labeled with TXRD or FITC, and then washed twice with phosphate buffer. Nuclei were stained with 10 i u M Hoechst 33342 (Calbiochem) and then examined with a fluorescence microscope (product name Laborlux, Leitz).
  • a fluorescence microscope product name Laborlux, Leitz
  • Fig. 1 (a) shows the result of using an antibody that recognizes the C terminus of the large subunit (pl7) of active caspase 3 as the primary antibody.
  • cells other than the interphase show tubulin polymerization and chromosome condensation, and are considered to be in the cell division phase. It can be seen that caspase 3 is active in the early, early, middle, late, and late stages of cell division.
  • HepG2 cells (1 X 10 6 / 6cm dish) were cultured in nocodazole (0. 8 ⁇ g / ml) in the presence, over time the cells were harvested and subjected to Western blotting, activity I spoon We detected caspase 3 (and caspase 8 ⁇ 9) active fragments as a result of cleavage by the above method.
  • the accumulation of mitotic cells by nocodazole treatment was confirmed by flow cytometry c
  • FIG. 2 (b) the active form fragment of caspase 3 was detected 12 hours after nocodazole treatment and increased with time.
  • caspase 8 and caspase 9 active form fragments were detected in the same time course, and the caspase 3 substrates poly ADP ribose polymerase (PARP), lamin Bl (LaminBl), protein kinase C ⁇ (PKC ⁇ ) cleavage (cleav age fragment) was also detected.
  • Lane A in the figure is a cell in which apoptosis was induced with an anti-Fas antibody as a control.
  • HeLa cells (4 ⁇ 10 5 Z6 cm dishes) were cultured for 24 hours and then cultured for 18 hours in the presence of 2.5 mM thymidine. After washing 3 times with phosphate buffer, a new medium was added and the cells were cultured for 10 hours, and again cultured in the presence of 2.5 mM thymidine for 14 hours. After washing 3 times with phosphate buffer, the cells are cultured in a new medium from which thymidine has been removed. The cells are collected over time, and fragments of caspases 3/8, 9 cleaved by active protein by Western blotting are collected. Detected. Progression of the cell cycle at each recovery was confirmed by flow cytometry.
  • the cells can be stopped at the boundary between almost 100% G1 phase and S phase.
  • Figure 3 (a) when thymidine is removed from the culture (release), the cells Begins around the cell cycle again, and after thymidine removal, the cells are in the G2ZM phase approximately 8-12 hours and reenter the G1 phase approximately 14 hours later.
  • caspase 3, caspase 8 and caspase 9 active form fragments were detected 10-14 hours after thymidine removal.
  • cleavage of the caspase 3 substrates poly ADP ribose polymerase (PARP), lamin Bl (LaminBl), and protein kinase C ⁇ (PKC ⁇ ) was also detected at the same time.
  • PARP poly ADP ribose polymerase
  • LaminBl lamin Bl
  • PKC ⁇ protein kinase C ⁇
  • lane N is the result of HeLa cells cultured under normal conditions
  • lane A is the result of cells in which apoptosis was induced with anti-Fas antibody.
  • caspase activation was confirmed specifically in the cell division phase of cancer cells. Next, its role was examined.
  • control medium was supplemented with 0.5% DMSO in the same manner as when the inhibitor was added.
  • Cells with inhibitor and control cells were both in G2ZM phase after 8 hours.
  • Example 3 Prevention of normal chromosome segregation during cell division by caspase inhibitor
  • HepG2 cells and HaLa cells were cultured in the presence of the caspase inhibitors to examine changes in the morphology of the nucleus.
  • HepG2 cells or HeLa cells were seeded at 2 ⁇ 10 5 cells per lwell in a 6-well dish with a cover glass at the bottom.
  • Z-Asp-CH2-DCB (final concentration 200 ⁇ ) or DMSO as a control was covered, and each day, the nuclei were stained with 10 ⁇ Hoechst 33342. The proportion was examined.
  • HeLa-GFP-H2B HeLa-GFP-H2B
  • histone H2B was fused with GFP and highly expressed were used.
  • Z-Asp-CH2-DCB final concentration 300 ⁇
  • DMSO final concentration 300 ⁇
  • the morphological changes of the nucleus were observed for 1 to 2 hours at 1 minute intervals using a confocal laser microscope.
  • Figure 6 shows typical nuclear morphology of cells treated with control and caspase inhibitors.
  • control cells with DMSO cell division progressed normally, and chromosome condensing power progressed to separation in about 90 to 120 minutes (Figs. 6a and b).
  • caspase was activated during the cell division stage of cancer cells, and caspase inhibitor was It has been shown to inhibit cancer cell division, especially chromosome segregation.
  • caspase 3 activity increases despite being in a non-apoptotic state, suggesting that some functions specific to cancer cells are occurring.
  • the possibility of functioning as a cell-specific cell growth inhibitor was considered. Therefore, in order to investigate this possibility, the following experiment was conducted.
  • WST-1 reagent (Roche) was used for the cell proliferation assay. HepG2 cells derived from liver cancer, HeLa cells derived from cervical cancer, or urkat cells derived from acute T cell leukemia were seeded in 96 well dishes at 4 ⁇ 10 3 cells per well and cultured for 24 hours. After each caspase inhibitor is prepared at each concentration, WST-1 reagent is prepared every day, and the dehydrogenase activity localized in mitochondria is measured by measuring the absorbance at 450 nm and 690 nm. And used as an index of cell proliferation.
  • caspase inhibitors the following compounds (1) to (8) were used.
  • the above (1) to (3) are cell membrane permeation-type versatile inhibitors.
  • a hydrophobic region of force-positive fibroblast growth factor is added to the N-terminal side of each of the caspase-specific inhibitors (4) to (8) above in order to enhance cell membrane permeability.
  • (1) is an inhibitor made by Peptide Institute
  • (2) to (8) are inhibitors made by Calbiochem. All inhibitors were dissolved in DMSO, and a portion of it was added to the culture medium, so the control burned DMSO at the same concentration as the inhibitor was added.
  • Z-Asp-CH2-DC is a cell membrane permeation inhibitor B, Boc-Asp (OMe) -FMK and Boc-Asp (OBzl) -CMK all inhibited the growth of HepG2, HeLa, and Jurkat cells in a concentration-dependent manner (FIG. 7).
  • Each caspase-specific inhibitor showed cytostatic activity against HepG2 cells, although there was a difference in the inhibitory effect (Fig. 8).
  • the anticancer agent of the present invention comprises a caspase inhibitor that has been shown to be effective in inhibiting the growth of cancer cells as an active ingredient, and solids such as liver cancer and cervical cancer It can be used as an anticancer agent against cancer.
  • the present invention can also be used as functional foods, supplements and the like having an anticancer effect and a cancer prevention effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a récemment découvert que la caspase était activée lors de l’étape de division cellulaire des cellules cancéreuses. L'administration d’un inhibiteur de la caspase permet de retarder l’évolution de la division cellulaire dans les cellules cancéreuses et d'inhiber la répartition chromosomique normale dans l’étape de division. De plus, on observe que l’administration d’un inhibiteur de la caspase a pour effet d‘inhiber la prolifération des cellules initiant le cancer du foie ou celles initiant le cancer du col de l’utérus, etc. Un agent anticancéreux, comprenant en tant que principe actif un inhibiteur de la caspase ayant un effet inhibiteur sur la prolifération cellulaire, conformément à la description précédente, peut être utilisé contre un cancer solide, tel qu‘un cancer du foie ou du col de l'utérus.
PCT/JP2005/021470 2004-11-22 2005-11-22 Activation de la caspase lors de l'etape de division cellulaire des cellules cancereuses et utilisation de l’inibiteur de la caspase dans un agent anticancereux et autres WO2006054773A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004337586 2004-11-22
JP2004-337586 2004-11-22

Publications (1)

Publication Number Publication Date
WO2006054773A1 true WO2006054773A1 (fr) 2006-05-26

Family

ID=36407303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/021470 WO2006054773A1 (fr) 2004-11-22 2005-11-22 Activation de la caspase lors de l'etape de division cellulaire des cellules cancereuses et utilisation de l’inibiteur de la caspase dans un agent anticancereux et autres

Country Status (1)

Country Link
WO (1) WO2006054773A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291705B2 (en) 2016-10-13 2022-04-05 Technion Research & Development Foundation Limited Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338474A (ja) * 2001-05-23 2002-11-27 Bizen Chemical Co Ltd カスパーゼ阻害剤
WO2004028474A2 (fr) * 2002-09-25 2004-04-08 University Of Rochester Inhibiteurs de la caspase utilises comme agents anticancereux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338474A (ja) * 2001-05-23 2002-11-27 Bizen Chemical Co Ltd カスパーゼ阻害剤
WO2004028474A2 (fr) * 2002-09-25 2004-04-08 University Of Rochester Inhibiteurs de la caspase utilises comme agents anticancereux

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARLSON K. ET AL: "Organophosphorus Compound-Induced Apoptosis in SH-SY5Y Human Neuroblastoma Cells", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 168, no. 2, 2000, pages 102 - 113, XP002995260 *
CHANDRA J. ET AL: "Protease Activation Is Required for Glucocorticoid-Induced Apoptosis in Chronic Lymphocytic Leukemic Lymphocytes", BLOOD, vol. 90, no. 9, 1997, pages 3673 - 3681, XP002193992 *
GASTMAN B.R. ET AL: "Tumor-induced Apoptosis of T Cells: Amplification by a Mitochondrial Cascade", CANCER RESEARCH, vol. 60, 2000, pages 6811 - 6817, XP002995261 *
HARADA J. ET AL: "Inhibitors of interleukin-1 beta-converting enzyme-family proteases (caspases) prevent apoptosis without affecting decreased cellular ability to reduce 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide in cerebellar granule neurons", BRAIN RESEARCH, vol. 793, 1998, pages 231 - 243, XP002995259 *
SCHLOSSER S. ET AL: "Inhibition of caspase-1 induces cell death in pancreatic carcinoma cells and potentially modulates expression levels of bcl-2 family proteins", FEBS LETTERS, vol. 491, 2001, pages 104 - 108, XP004257283 *
SIDDIQUI R.A. ET AL: "Prevention of docosahexaenoic acid-induced cytotoxicity by phosphatidic acid in Jurkat leukemic cells: the role of protein phosphatase-1", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1541, 2001, pages 188 - 200, XP004330476 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291705B2 (en) 2016-10-13 2022-04-05 Technion Research & Development Foundation Limited Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing

Similar Documents

Publication Publication Date Title
Schulze-Bergkamen et al. Apoptosis in cancer—implications for therapy
US20050042213A1 (en) Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
KR101549245B1 (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
US20060094676A1 (en) Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
EP3542821A1 (fr) MOLÉCULE INDUISANT LA DÉGRADATION DE p53 ET COMPOSITION PHARMACEUTIQUE
KR20210056959A (ko) 간암의 예방 또는 치료용 조성물
KR20200044695A (ko) Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물
WO2007061256A1 (fr) Utilisation nouvelle de l'ubiquitine hydrolase-l1 a terminaison c
US20140256614A1 (en) Compositions and methods for augmenting permeability barriers
US20210205349A1 (en) Inhibition of ngly1 for the treatment of cancer
Li et al. USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target
AU2007221863A1 (en) Treatment of chemotherapy -or radiothereapy-resistant tumors
KR20140098870A (ko) 다발성 골수종 세포를 사멸시키기 위한 ｅＩＦ-５Ａ의 용도
WO2006054773A1 (fr) Activation de la caspase lors de l'etape de division cellulaire des cellules cancereuses et utilisation de l’inibiteur de la caspase dans un agent anticancereux et autres
JP2006169242A (ja) がん細胞の細胞分裂期におけるカスパーゼの活性化と、カスパーゼ阻害物質の抗がん剤などへの利用
ES2396115T3 (es) Uso de inhibidores de la degradación de p27, en particular argirina y derivados de la misma, para el tratamiento del cáncer
US20070238677A1 (en) Pharmaceutical Composition Containing Hshrd3
US20130157959A1 (en) Use of hades as tumor suppressor target
WO2013122321A1 (fr) Utilisation de hdac6 en tant que marqueur d'hépatome et agent thérapeutique
US20080299123A1 (en) Treatment of chemotherapy- or radiotherapy-resistant tumors
KR101776864B1 (ko) Npffr2 억제제를 유효성분으로 포함하는 암 전이 억제 및 암 치료용 조성물
KR100861464B1 (ko) 발암/전이유전자 ｔｉｐ41과 이에 의해 코드되는 단백질 및이를 이용한 발암 및 전이 진단 키트
AU2004288034A1 (en) BACE455, an alternative splice variant of the human beta-secretase
Bartling et al. Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors
KR102328654B1 (ko) 암의 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05809528

Country of ref document: EP

Kind code of ref document: A1